Incyte Corporation

In the second quarter of 2026, total revenue was $1.67 billion, up 38% year over year, and total net product sales were $1.49 billion, up 40%; excluding a one-time noncash CMS settlement benefit, total net sales increased 17%. Jakafi sales were $817 million, up 7% year over year; Opzelura sales were $450 million, including a $246 million one-time noncash benefit; Niktimvo sales were $60 million; Monjuvi sales were $54 million; and Zynyz sales were $50 million. GAAP expenses were $976 million, up 42%; GAAP cost of goods was $105 million, or 7% of total net sales; GAAP R&D was $517 million, up 4%; and GAAP SG&A was $352 million, up 6%. The company ended the quarter with $4.5 billion in cash and cash equivalents. Full-year 2026 guidance was raised to total net sales of $5.130 billion to $5.260 billion, Opzelura net sales of $1.050 billion to $1.1 billion, hematology and oncology net sales of $860 million to $890 million, GAAP R&D and SG&A of $4.915 billion to $4.995 billion, and non-GAAP R&D and SG&A of $4.625 billion to $4.695 billion. Management said Jakafi XR should contribute $40 million to $50 million in full-year sales and that COGS should be 8% to 9% of full-year net sales.

Bill Meury framed the quarter as evidence that Incyte is moving from dependence on a single cornerstone product to a multi-driver company. He emphasized broad commercial growth, key approvals and launches, late-stage pipeline advancement, and the addition of latarcibart as a strategically attractive hematology asset. His tone was confident and execution-focused, repeatedly stressing that the company is now positioned for multiple near-term launches and a more durable long-term growth profile.

Suketu Upadhyay highlighted the quarter’s strong operating performance and the main drivers behind the guidance update. He pointed to the $246 million noncash CMS-related Opzelura benefit, said underlying total net sales rose 17% excluding that item, and noted that GAAP expenses were affected by the comparison against the prior-year Novartis settlement. He also gave specific expense guidance: COGS is expected to run at 8% to 9% of full-year net sales, and the updated operating expense outlook reflects the Vega acquisition, including an approximately $1.270 billion upfront payment and about $50 million in ongoing Phase III costs for latarcibart.

Analysts focused heavily on 989’s regulatory path in MF, with questions about endpoint design, whether anemia and composite measures could be included, and how dosing might differ for type 1 versus non-type 1 patients. Management said it is in constructive discussions with FDA and is evaluating both standard endpoints such as SVR35 and TSS50 and alternative endpoints that better reflect 989’s mechanism and hemoglobin benefits; they also said the current plan is to study MF in both type 1 and non-type 1 patients. Other notable Q&A centered on the Halozyme collaboration for subcutaneous 989, the G12D program’s ESMO data and competitive positioning, the potential for latarcibart beyond VWD, the Jakafi XR rollout, and whether Incyte might opt into Syndax’s IPF data for Niktimvo. Management said XR reimbursement has already started, G12D data should be materially derisking, latarcibart could support a Hemlibra-like opportunity if Phase III succeeds, and any Niktimvo IPF decision will depend on the data shared by Syndax.